14 results
Search Results
2. Case-control study of Epstein-Barr virus and Helicobacter pylori serology in Latin American patients with gastric disease.
- Author
-
Cárdenas-Mondragón, M G, Torres, J, Flores-Luna, L, Camorlinga-Ponce, M, Carreón-Talavera, R, Gomez-Delgado, A, Kasamatsu, E, and Fuentes-Pananá, E M
- Subjects
HELICOBACTER pylori infections ,GASTRIC mucosa ,EPSTEIN-Barr virus ,DISEASE progression ,ADENOCARCINOMA ,ATROPHIC gastritis ,TUMORS ,DISEASE risk factors - Abstract
Background:Chronic tissue damage induced by Helicobacter pylori (HP)-driven inflammation is considered the main risk of gastric carcinoma (GC). Epstein-Barr virus (EBV) infection has also been associated with GC. In this study, we aim to address the role of EBV in inflammatory GC precursor lesions and its added risk to HP infection.Methods:Antibodies against EBV, HP and the bacterial virulence factor CagA were measured in sera from 525 Mexican and Paraguayan patients with gastric disease. Gastric samples were characterised according to the updated Sydney classification and associations were estimated between antibody responses and severity of both tissue damage and inflammation.Results:We found significant associations (odd ratios and trends) between EBV and HP copositivity and premalignant lesions and intestinal-type GC. The EBV and HP coinfection was also significantly associated with increased infiltration of immune cells. No association was found between EBV and the less inflammation-driven diffuse-type GC.Conclusions:Our study suggests that EBV co-participates with HP to induce severe inflammation, increasing the risk of progression to intestinal-type GC. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
3. The impact of plasma epstein-barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study.
- Author
-
Tang, L-Q, Chen, Q-Y, Guo, S-S, Chen, W-H, Li, C-F, Zhang, L, Lai, X-P, He, Y, Xu, Y-X-X, Hu, D-P, Wen, S-H, Peng, Y-T, Liu, H, Liu, L-T, Yan, S-M, Guo, L, Zhao, C, Cao, K-J, Liu, Q, and Qian, C-N
- Subjects
EPSTEIN-Barr virus ,PROGNOSIS ,NASOPHARYNX cancer ,FIBRINOGEN ,BIOMARKERS ,SCIENTIFIC observation ,PHYSIOLOGY - Abstract
Background:The impact of combining plasma fibrinogen levels with Epstein-Barr Virus DNA (EBV DNA) levels on the prognosis for patients with nasopharyngeal carcinoma (NPC) was evaluated.Methods:In this observational study, 2563 patients with non-metastatic NPC were evaluated for the effects of circulating plasma fibrinogen and EBV DNA levels on disease-free survival (DFS), distant metastasis-free survival (DMFS), and overall survival (OS).Results:Compared with the bottom biomarker tertiles, TNM stage-adjusted hazard ratios (HR, 95% confidence intervals (CIs)) for predicting DFS in fibrinogen tertiles 2 to 3 were 1.26 (1.00 to 1.60) and 1.81 (1.45 to 2.26), respectively; HR for EBV DNA tertiles 2 to 3 were 1.49 (1.12 to 1.98) and 4.24 (3.27 to 5.49), respectively. After additional adjustment for established risk factors, both biomarkers were still associated (P for trend <0.001) with reduced DFS (HR: 1.79, 95% CI, 1.43 to 2.25 for top fibrinogen tertiles; HR: 4.04, 95% CI: 3.10 to 5.27 for top EBV DNA tertiles compared with the bottom tertiles). For patients with advanced-stage disease, those with high fibrinogen levels (⩾3.34 g l
−1 ) presented with worse DFS, regardless of EBV DNA ⩾4000 or <4000 copies ml−1 subgroup. Similar findings were observed for DMFS and OS.Conclusions:Circulating fibrinogen and EBV DNA significantly correlate with NPC patients survival. Combined fibrinogen and EBV DNA data lead to improved prognostic prediction in advanced-stage disease. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
4. Somatostatin Receptor 1, a novel EBV-associated CpG hypermethylated gene, contributes to the pathogenesis of EBV-associated gastric cancer.
- Author
-
Zhao, J, Liang, Q, Cheung, K-F, Kang, W, Dong, Y, Lung, R W-M, Tong, J H-M, To, K-F, Sung, J J Y, and Yu, J
- Subjects
STOMACH cancer treatment ,SOMATOSTATIN receptors ,METHYLATION ,CPG nucleotides ,EPSTEIN-Barr virus ,PROMOTERS (Genetics) ,TRANSCRIPTION factors - Abstract
Background:Somatostatin receptor 1 (SSTR1) was preferentially methylated in Epstein-Barr virus (EBV)-positive gastric cancer using promoter methylation array. We aimed to analyse the epigenetic alteration and biological function of SSTR1 in EBV-associated gastric cancer (EBVaGC).Methods:Promoter methylation was examined by combined bisulphite restriction analysis (COBRA) and pyrosequencing. The biological functions of SSTR1 were evaluated by loss- and gain-of-function assays.Results:Promoter hypermethylation of SSTR1 was detected in EBV-positive gastric cancer cell lines (AGS-EBV) with SSTR1 transcriptional silence, but not in EBV-negative gastric cancer cell lines with SSTR1 expression. Expression level of SSTR1 was restored in AGS-EBV by exposure to demethylating agent. Moreover, methylation level of SSTR1 was significantly higher in EBV-positive primary gastric cancers compared with EBV-negative gastric cancers (P=0.004). Knock-down of SSTR1 in gastric cancer cell lines (AGS and BGC823) increased cell proliferation and colony formation ability, and promoted G1 to S-phase transition, enhanced cell migration and invasive ability. In contrast, ectopic expression of SSTR1 in gastric cancer cell lines (MKN28 and MGC803) significantly suppressed cell growth in culture conditions and reduced tumour size in nude mice. The tumour suppressive effect of SSTR1 was associated with upregulation of cyclin-dependent kinase inhibitors (p16, p15, p27 and p21); downregulation of oncogenes (MYC and MDM2), key cell proliferation and pro-survival regulators (PI3KR1, AKT, BCL-XL and MET); and inhibition of the migration/invasion-related genes (integrins, MMP1 (matrix metallopeptidase 1), PLAUR (plasminogen activator urokinase receptor) and IL8 (interleukin 8)).Conclusion:Somatostatin receptor 1 is a novel methylated gene driven by EBV infection in gastric cancer cells and acts as a potential tumour suppressor. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
5. Reply: Is Epstein-Barr virus associated with aggressive forms of breast cancer?
- Author
-
Mazouni, C., Fina, F., and Martin, P.-M.
- Subjects
LETTERS to the editor ,EPSTEIN-Barr virus ,BREAST cancer - Abstract
A response by C. Mazouni and colleagues to a letter to the editor on their article "Epstein-Barr virus as a market of biological aggressiveness in breast cancer" in the 2011 issue is presented.
- Published
- 2011
- Full Text
- View/download PDF
6. c-Myc and EBV-LMP1: two opposing regulators of the HLA class I antigen presentation machinery in epithelial cells.
- Author
-
Tudor, C S, Dawson, C W, Eckhardt, J, Niedobitek, G, Büttner, A C, Seliger, B, Hartmann, A, and Buettner, M
- Subjects
CANCER research ,EPITHELIAL cells ,EPSTEIN-Barr virus ,MEMBRANE proteins ,HLA histocompatibility antigens ,ANTIGEN presentation ,IMMUNE system ,CELL lines ,GENE expression - Abstract
Background:Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) up-regulates the human leukocyte antigen (HLA) class I antigen presentation machinery (APM). This appears counterintuitive with immune evasion in EBV-associated tumours like nasopharyngeal carcinoma (NPC).Methods:Latent membrane protein 1-transfected epithelial cell lines were used as a model system to study the impact of LMP1 and c-Myc on HLA class I components. The expression of components of the HLA class I APM, c-Myc and Ki-67 was analysed in LMP1+ and LMP1− NPC by immunohistochemistry.Results:In epithelial cells, LMP1 up-regulated HLA class I APM. This effect could be counteracted by c-Myc, which itself was up-regulated by LMP1 apparently through IL6 induction and Jak3/STAT3 activation. Studies of NPC biopsies revealed down-regulation of HLA class I APM expression. No difference was observed between LMP1+ and LMP1− NPC. However, expression of Ki-67 and c-Myc were up-regulated in LMP1+ tumours.Conclusion:These findings raise the possibility that c-Myc activation in NPC might antagonise the effect of LMP1 on HLA class I expression thus contributing to immune escape of tumour cells. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
7. Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease.
- Author
-
McAulay, K. A., Haque, T., and Crawford, D. H.
- Subjects
GENETIC research ,LYMPHATIC diseases ,LYMPHOPROLIFERATIVE disorders ,TUMOR necrosis factors ,NECROSIS ,TUMOR suppressor genes ,GENETIC polymorphisms ,ENZYME-linked immunosorbent assay ,DISEASE risk factors ,CELL receptors ,COMPARATIVE studies ,EPSTEIN-Barr virus ,GENES ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,TRANSPLANTATION of organs, tissues, etc. ,EVALUATION research ,HAPLOTYPES - Abstract
Background: Epstein-Barr virus-positive post-transplant lymphoproliferative disease (PTLD) is a potentially lethal complication of iatrogenic immunosupression after transplantation. Predicting the development of PTLD allowing early and effective intervention is therefore of importance. Polymorphisms within cytokine genes are implicated in susceptibility to, and progression of, disease however the published data are often conflicting. We undertook investigation of polymorphic alleles within cytokine genes in PTLD and non-PTLD transplant cohorts to determine risk factors for disease.Methods: SSP-PCR was used to analyse single nucleotide polymorphism within tumour necrosis factor (TNF)-alpha, interleukin- 1, -6, -10 and lymphotoxin-alpha genes. The TNF-alpha levels were measured by standard enzyme-linked immuno-absorbant assay.Results: We show an association between variant alleles within the TNF-alpha promoter (-1031C (P=0.005)); -863A (P=0.0001) and TNF receptor I promoter regions (-201T (P=0.02)); -1135C (P=0.03) with the development of PTLD. We also show an association with TNF-alpha promoter haplotypes with haplotype-3 significantly increased (P=0.0001) and haplotype-1 decreased (P=0.02) in PTLD patients compared to transplant controls. Furthermore, we show a significant increase (P=0.02) in the level of TNF-alpha in PTLD patient plasma (range 0-97.97 pg ml(-1)) compared to transplant controls (0-8.147 pg ml(-1)), with the highest levels found in individuals carrying the variant alleles.Conclusion: We suggest that genetic variation within TNF-alpha loci and the level of plasma cytokine could be used as a predictive risk factor for the development of PTLD. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
8. Outcome of a risk-related therapeutic strategy used prospectively in a population-based study of Hodgkin's lymphoma in adolescents.
- Author
-
Jones, G. L., Taylor, P. R. A., Windebank, K. P., Hoye, N. A., Lucraft, H., Wood, K., Angus, B., and Proctor, S. J.
- Subjects
HODGKIN'S disease ,EPSTEIN-Barr virus ,CYSTIC fibrosis ,DRUG therapy ,RADIOTHERAPY - Abstract
The aim was to assess outcome in a population-based cohort of adolescents with Hodgkin's lymphoma (HL) diagnosed in the UK's northern region over a 10-year period. Among a population of 3.09 million, 55 of 676 patients (8%) diagnosed with HL were aged 13–19. Seven had nodular lymphocyte-predominant HL, 48 classical HL (cHL). Of the latter, 36 were 16 years. Application of the Scottish and Newcastle Lymphoma Group (SNLG) prognostic index meant 21 patients were considered high risk (index 0.5). They received PVACEBOP multi-agent chemotherapy as primary therapy. Standard risk patients (SNLG index <0.5) were treated with standard ChlVPP or ABVD chemotherapy±radiotherapy. Scottish and Newcastle Lymphoma Group indexing is not valid for patients under 16. Twelve patients therefore received UKCCSG protocols (n=8), ABVD plus radiotherapy (n=2), or PVACEBOP (n=2). Forty-six patients with cHL (96%) achieved complete remission. Seven patients relapsed but all entered complete remission after salvage therapy. Five patients died: three of HL, one in an accident and one of disseminated varicella complicating cystic fibrosis. Five- and 10-year overall survival was 93 and 86%, respectively; disease-specific survival was 95 and 92%. The data suggest that older adolescents with high-risk HL require intensive protocols as primary therapy to secure optimal outcome.British Journal of Cancer (2007) 97, 29–36. doi:10.1038/sj.bjc.6603809 www.bjcancer.com Published online 29 May 2007 [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
9. Epstein-Barr virus gene expression in human breast cancer: protagonist or passenger?
- Author
-
Xue, S A, Lampert, I A, Haldane, J S, Bridger, J E, and Griffin, B E
- Subjects
BREAST cancer ,EPSTEIN-Barr virus ,GENE expression ,LYMPHOCYTES ,ESTROGEN ,DNA analysis ,PROTEIN analysis ,PROTEINS ,CANCER ,DNA probes ,GENES ,T cells ,POLYMERASE chain reaction ,EPSTEIN-Barr virus diseases ,BREAST tumors ,DISEASE complications - Abstract
The presence and transcriptional expression of Epstein-Barr virus (EBV)-encoded genes, oestrogen receptor (ER) status and degree of lymphocyte infiltration were evaluated in 15 mastectomy-removed breast cancer samples, mostly of ductal origin. With regard to these parameters, the tumours were heterogeneous. Viral genes, including EBNA1 - a universal EBV marker - and others, selected in part on the basis of expression in other EBV-associated carcinomas and/or presence in an epithelial cell immortalising subfragment p31 of viral DNA, were detected in up to 40% of the breast malignancies. The small viral RNAs, EBERs, were not observed. In culture, p31 EBV DNA, alone among EBV fragments, stimulated the growth of human breast-milk epithelial cells. There was no correlation between viral and ER expression and tumours were heterogeneous with regard to their invasive lymphocytes: of three studied in detail, one contained none, another had (mainly) T-lymphocyte aggregates on the tumour periphery, and a third (BC 12) was infiltrated with both T- and B-lymphocytes. BC 12 differed in several aspects from other malignancies in expressing a transcriptional activator (BZLF1) associated with overcoming virus latency, and failing to express a viral oncogene, BARF1. Arguments are given for EBV as a protagonist cocarcinogen in some breast malignancies. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
10. Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents.
- Author
-
Alexander, F E, Jarrett, R F, Lawrence, D, Armstrong, A A, Freeland, J, Gokhale, D A, Kane, E, Taylor, G M, Wright, D H, and Cartwright, R A
- Subjects
HODGKIN'S disease ,EPSTEIN-Barr virus - Abstract
A UK population-based case-control study of Hodgkin's disease (HD) in young adults (16-24 years) included 118 cases and 237 controls matched on year of birth, gender and county of residence. The majority (103) of the cases were classified by Epstein-Barr virus (EBV) status (EBV present in Reed-Stenberg cells), with 19 being EBV-positive. Analyses using conditional logistic regression are presented of subject reports of prior infectious disease (infectious mononucleosis (IM), chicken pox, measles, mumps, pertussis and rubella). In these analyses HD cases are compared with matched controls, EBV-positive cases and EBV-negative cases are compared separately with their controls and formal tests of differences of association by EBV status are applied. A prior history of IM was positively associated with HD (odds ratio (OR) = 2.43, 95% confidence interval (CI) = 1.10-5.33) and with EBV-positive HD (OR = 9.16, 95% CI = 1.07-78.31) and the difference between EBV-positive and EBV-negative HD was statistically significant (P = 0.013). The remaining infectious illnesses (combined) were negatively associated with HD, EBV-positive HD and EBV-negative HD (in the total series, for > or =2 episodes compared with < or =1, OR = 0.45, 95% CI = 0.25-0.83). These results support previous evidence that early exposure to infection protects against HD and that IM increases subsequent risk; the comparisons of EBV-positive and EBV-negative HD are new and generate hypotheses for further study. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
11. Epstein–Barr virus expression in Hodgkin’s disease in relation to patient characteristics, serum factors and blood lymphocyte function.
- Author
-
Axdorph, U, Porwit-MacDonald, A, Sjöberg, J, Grimfors, G, Ekman, M, Wang, W, Biberfeld, P, and Björkholm, M
- Subjects
EPSTEIN-Barr virus ,HODGKIN'S disease - Abstract
Epstein-Barr virus (EBV) expression was investigated by immunohistochemistry (latent membrane protein 1 [LMP-1]) and in situ hybridization (EBV encoded RNA [EBER]) in biopsies from 95 patients with untreated Hodgkin's disease (HD). Tumour EBV status was related to EBV antibody titres, spontaneous and concanavallin A induced blood lymphocyte DNA synthesis, serum levels of soluble (s) CD4, sCD8, sCD25, sCD30, sCD54, β2-microglobulin, thymidine-kinase, routine chemistry, patient characteristics, complete remission and survival. The median follow-up time was 145 months (range 60-257). Tumour EBV-positive (n = 30; 33%) and negative (n = 62; 67%) patients did not differ with regard to sex, age, stage, presence of bulky disease or B-symptoms, remission rate or survival. The proportion of EBV+ cases was significantly higher among patients with mixed cellularity histopathology (58%) as compared to the nodular sclerosis subtype (18%; P < 0.001). The total white blood cell (WBC) counts were significantly lower in EBV+ patients (P < 0.01), who also had significantly higher levels of sCD54 (P < 0.02) and a tendency towards lower levels of sCD30 (P = 0.056). Patients in the tumour EBV+ group had significantly higher IgG antibody titres to restricted early antigen (EA-R) (P < 0.02). Hence, clinical features and outcome were not related to tumour EBV status. However, HD patients with EBV+ tumours had elevated sCD54 levels, higher antibody titres to EA-R and decreased total WBC counts. A potential causal relationship between EBV tumour status and these findings needs to be further explored. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
12. Human herpes virus 6 or Epstein-Barr virus were not detected in Guthrie cards from children who later developed leukaemia.
- Author
-
Bogdanovic, G., Jernberg, Å G., Priftakis, P., Griliner, L., Gustafsson, B., Jernberg, A G, and Grillner, L
- Subjects
HERPESVIRUS diseases ,EPSTEIN-Barr virus ,CANCER patients ,LYMPHOBLASTIC leukemia ,GENES ,DNA ,RESEARCH ,ANIMAL experimentation ,RESEARCH methodology ,EVALUATION research ,COMPARATIVE studies ,HERPESVIRUSES ,TUMORS ,POLYMERASE chain reaction ,EPSTEIN-Barr virus diseases ,DISEASE complications - Abstract
To investigate if children who later developed acute lymphoblastic leukaemia (ALL) were prenatally infected with HHV-6 and/or EBV, Guthrie cards taken at birth were analysed by PCR. Guthrie cards from 54 patients with ALL and 47 healthy controls matched for age and birth place were tested negative for both HHV-6 and EBV DNA. All samples contained amplifiable DNA when tested by HLA-DQ PCR. Our negative findings suggest that childhood ALL is unlikely to be associated with an in utero infection with EBV or HHV-6. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
13. Delayed infection, late tonsillectomy or adenoidectomy and adult leukaemia: a case-control study.
- Author
-
Vineis, P, Miligi, L, Crosignani, P, Davico, L, Fontana, A, Masala, G, Nanni, O, Ramazzotti, V, Rodella, S, Stagnaro, E, Tumino, R, Viganò, C, Vindigni, C, and Costantini, A S
- Subjects
LYMPHOCYTIC leukemia ,MYELOID leukemia ,ADENOIDECTOMY ,LEUKEMIA ,SURGICAL complications ,CASE-control method ,CELL division ,TONSILLECTOMY ,EPSTEIN-Barr virus ,EPSTEIN-Barr virus diseases ,DISEASE complications - Abstract
In a population-based case-control study among adults in Italy, of 261 lymphoid and 313 myeloid leukaemias and 1718 controls, a later age at adenoidectomy and tonsillectomy (after age 10 years) increased considerably the risk of lymphocytic (but not myeloid) leukaemia (odds ratio 4.2, 95% confidence interval 1.1-16.2). We propose that late infection is a proliferative stimulus for B-cells. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
14. Is Epstein-Barr virus associated with aggressive forms of breast cancer?
- Author
-
Khan, G., Philip, P. S., and Al Ashari, M.
- Subjects
LETTERS to the editor ,EPSTEIN-Barr virus ,BREAST cancer - Abstract
A letter to the editor is presented in response to the article "Esptein-Barr virus as a marker of biological aggressiveness in breast cancer," by C. Mazouni and colleagues in the 2011 issue of "British Journal of Cancer."
- Published
- 2011
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.